The filing discloses the adoption of a severance and change in control program, which is a compensatory arrangement rather than a specific executive departure or appointment.

and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

VP of Finance, Senior Controller, Treasurer and Principal Accounting Officer — John Militello: John Militello resigned to pursue other opportunities.

Completion of Acquisition or Disposition of Assets. On June 10, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) completed the previously disclosed sale (the “Asset Sale”) of its Rare Pediatric Disease Priority Review Voucher (“PRV”) to a large pharmaceutical company. The PRV was originally issued in connection with the FDA’s approval of the Company’s biologics license application for KRESLADI™ (marnetegragene autotemcel), an autologous hematopoietic stem cell-based gene therapy indicated f…

and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Entry into a Material Definitive Agreement. On April 26, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a definitive asset purchase agreement (the “PRV APA”) pursuant to which the Company has agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”). As previously disclosed, the PRV was originally issued in connection with the FDA’s approval of the Company’s biologics license application for KRESLADI™ (marnetegragene autotemcel), an autologous hematopoietic stem…

Regulation FD Disclosure. On April 28, 2026, the Company issued a press release announcing that it had entered into the PRV APA, a copy of the which is furnished as Exhibit 99.1 hereto. The information under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into the…

Entry into a Material Definitive Agreement. On March 10, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Sales Agent”), with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.01 per share, having an aggregate offering price of up to $100,000,000 (the “Shares”), through the Sa…

Termination of a Material Definitive Agreement. Upon entry into the Sales Agreement, the Company terminated its prior “at-the-market” sales agreement with Cowen and Company, LLC, an affiliate of TD Securities (USA) LLC, dated February 28, 2022, (the “Prior Sales Agreement”), as amended by Amendment No. 1 to the Prior Sales Agreement, dated as of September 12, 2023 (“Amendment No. 1”), pursuant to which the Company could offer and sell, from time to time through Cowen and Company, LLC, as its…

and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Other Events. On October 14, 2025, Rocket Pharmaceuticals, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) has accepted resubmission of the Biologics License Application (BLA) for KRESLADI™ (marnetegragene autotemcel; marne-cel), a lentiviral vector (LV)-based investigational gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I), a rare genetic immune disorder that predisposes patients to recurrent and fatal infections and is near-uniformly fata…

Other Events. On October 3, 2025, Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) reported that it has voluntarily withdrawn its Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”) for mozafancogene autotemcel (also known as “Fanskya,” “Fanca-cel,” or “RP-L102”), an investigational gene therapy for the treatment of Fanconi Anemia (“FA”). This decision follows the Company’s previously announced corporate prioritization, under which Rocket is focusing…

Director — Pedro Granadillo: Mr. Granadillo resigned from the Board of Directors without any disagreement on matters relating to the Company’s operations, policies or practices.

Director — Dr. Gotham Makker: Dr. Makker resigned from the Board of Directors and was succeeded by Dr. Peter Fong.

Entry into a Material Definitive Agreement In connection with the previously announced departure of Dr. Kinnari Patel to accept a role as a venture partner at RTW Investments LP, on September 11, 2025, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a Separation and Release Agreement (the “Separation Agreement”) with Dr. Patel. Pursuant to the Separation Agreement, Dr. Patel agreed to a general release of claims in favor of the Company and its affiliates and agreed to certain restri…

Chief Financial Officer — Aaron Ondrey: Aaron Ondrey resigned as Chief Financial Officer to pursue other opportunities.

President, Head of Research and Development — Dr. Kinnari Patel: Dr. Kinnari Patel is leaving the Company to accept a role as a venture partner at RTW Investments LP.

and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Other Events. On July 24, 2025, Rocket Pharmaceuticals, Inc. (the “Company”) issued a press release announcing a strategic corporate reorganization and pipeline prioritization aimed at maximizing near-term value, extending operational runway into the second quarter of 2027, and positioning the company for sustained long-term growth (the “Plan”). The full text of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference. Forward-Looking Statements Except for…

Costs Associated With Exit or Disposal Activities. On July 23, 2025, Rocket Pharmaceuticals, Inc. (the “Company”) began implementation of a strategic corporate reorganization and pipeline prioritization aimed at maximizing near-term value, extending operational runway into the second quarter of 2027, and positioning the company for sustained long-term growth (the “Plan”). The Company’s Board of Directors unanimously approved the Plan on June 18, 2025. As part of the restructuring, the Company…

President, Head of R&D — Dr. Kinnari Patel: Dr. Kinnari Patel transitioned from Chief Operating Officer to President, Head of R&D.

Results of Operations and Financial Condition. On May 8, 2025, Rocket Pharmaceuticals, Inc. (the “Company”) announced certain preliminary financial information for the quarter ended March 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Ac…

Director — R. Keith Woods: Mr. Woods is leaving the Board to take a COO position with another company.

Chief Commercial & Medical Affairs Officer — Sarbani Chaudhuri: The company hired a highly experienced executive to lead commercial and medical affairs.